Apimeds Pharmaceuticals US Inc.
Organization details
- Legal name
- Apimeds Pharmaceuticals US Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Matawan
- Headquarters state / province
- New Jersey
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- APUS
- Primary stock exchange
- NYSE American
Identifiers
- SEC CIK
- 0001894525
- EIN
- 85-1099700
Board of directors
-
Bennett Weintraub · DirectorSince 2025
-
Carol A. O'donnell · DirectorSince 2025
-
Christopher Kim · Director · Chairman and CMOSince 2025
-
Elona Kogan · DirectorSince 2025
-
Erik C. Emerson · Director · Chief Executive OfficerSince 2025
-
Hankil Yoon · DirectorSince 2025
-
Jakap Koo · DirectorSince 2025
Chief executives
Board connections
1 of this board's directors also sit on 1 other board.
- via Carol A. O'donnell
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 16, 2025 | Christopher Kim Director, Officer (Chairman and CMO) | Grant or award | +250,000 | — | — |
| May 16, 2025 | Erik C. Emerson Director, Officer (Chief Executive Officer) | Grant or award | +750,000 | — | — |
| May 14, 2025 | Christopher Kim Director, Officer (Chairman and CMO) | Open-market purchase | +7,730 | $1.86 | $14,378 |
| May 13, 2025 | Christopher Kim Director, Officer (Chairman and CMO) | Open-market purchase | +19,770 | $1.82 | $35,981 |
| May 12, 2025 | Jakap Koo Director | Open-market purchase | +28,500 | $1.99 | $56,715 |
| May 12, 2025 | Inscobee Inc. 10% owner | Open-market purchase | +500,000 | $4.00 | $2,000,000 |
| May 12, 2025 | Inscobee Inc. 10% owner | Derivative conversion | +182,002 | $2.60 | $473,205 |
| May 12, 2025 | Inscobee Inc. 10% owner | Derivative conversion | +71,090 | $2.60 | $184,834 |
| May 12, 2025 | Inscobee Inc. 10% owner | Derivative conversion | +44,041 | $2.60 | $114,507 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Apimeds Pharmaceuticals US Inc.
Who is the CEO of Apimeds Pharmaceuticals US Inc.?
Erik C. Emerson has been Apimeds Pharmaceuticals US Inc.'s Chief Executive Officer since March 2025.
How many directors are on Apimeds Pharmaceuticals US Inc.'s board?
Apimeds Pharmaceuticals US Inc.'s board has 7 directors: Bennett Weintraub, Carol A. O'donnell, Christopher Kim, Elona Kogan, Erik C. Emerson, Hankil Yoon and Jakap Koo.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="apimeds-pharmaceuticals-us-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.